Xuanzhu Biopharmaceutical (HKG:2575) said its innovative drug Anjiuwei will remain on China's National Reimbursement Drug List in 2025, according to a Monday Hong Kong bourse filing.
Anjiuwei, approved in June 2023 for duodenal ulcers, was first added to the list in December 2023.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments